![](https://healthysavings.in/wp-content/uploads/2022/10/Glenmark.jpg)
Glenmark launches first triple fixed-dose combination Teneligliptin with Pioglitazone and Metformin in India
In India, Glenmark Pharmaceuticals (Glenmark), a pharmaceutical company focused on innovation, has introduced the first triple fixed-dose combination of Teneligliptin, Pioglitazone, and Metformin. One frequently used DPP4 inhibitor is teneligliptin (Dipeptidyl Peptidase 4 inhibitor). The sustained release (SR) formulation of this FDC, sold under the trade name Zita-PioMet, contains the active ingredients teneligliptin (20 mg), pioglitazone